The aim of the present study was to formulate levocetirizine hydrochloride (LCD)-loaded chitosan nanoparticles at submicron level with high entrapment efficiency and prolonged effect for optimizing the plasma drug concentration enhancing bioavailability. LCD was successfully incorporated into chitosan nanoparticles by spray drying for the purpose of oral application. In vitro characteristics were evaluated in detail. LCD was successfully loaded into the polymeric matrices by spray drying. Characterization of the nanoparticles including encapsulation efficiency, particle size, zeta potential, morphology, polydispersity index, solid-state characterizations, and LCD quantification by high performance liquid chromatography was performed. The release pattern of LCD from the nanoparticles was determined using a dialysis tube in simulated intestinal fluid (pH 6.8). In vitro release profiles indicated prolonged release of LCD from the nanoparticles that followed the Korsmeyer-Peppas kinetic model. Chitosan-based LCD-loaded polymeric nanoparticles appear to be a promising drug delivery system for the active agent.
22 September 2016 in Journal of Microencapsulation
Objectives of this study were the delivery of gamma aminobutyric acid (GABA) into the brain by means of developing brain targeted, nanosized, non-toxic and biocompatible polymeric nanoparticles, and investigating their effectiveness in epilepsy. For this purpose, GABA conjugated N,N-dimethylacrylamide-based pegylated nanoparticles were designed and characterised for particle size, zeta potential, pH, morphology, DSC, XRD, FTIR, GABA quantification and in vitro release. Formulations showed smaller particle size, cationic zeta potential characteristic, possible GABA polymeric matrix interaction and prolonged release pattern. Brain responses were examined using epileptic rats. Both formulations prepared were found to increase latency of seizure, decrease ending time of convulsion, duration of severe convulsion and mortality rate significantly compared with GABA solution. When GABA concentration was measured in Stratum corsatum, there was no statistical difference between GABA solution and formulations. All findings suggested enhancement in all phases of seizures indicating efficient delivery of GABA into the brain via formulations.
1 February 2021 in Journal of Drug Delivery Science and Technology
Objective: The purpose of this study was the design ibuprofen (IBU) loaded unique Eudragit® RS 100 (ERS) and/or octadecylamine modified PLGA nanoparticles (NPs) for cancer treatment. Significance: The rational for this approach is to bring a new approach to cancer treatment with modification of IBU loaded PLGA NPs with ERS and/or octadecylamine by means of smaller particle size (PS), cationic surface, biocompatible nature and investigating their selective efficacy on lung cell lines (A549 lung cancer cell and CCD-19Lu normal cell line). Methods: IBU encapsulated PLGA based NPs were prepared and characterized for physical and solid-state analyses. In vitro release, MTT and determination of apoptotic pathways were performed. Results: Considering characterizations; B, C, E, F, H and K formulations with higher EE%, smaller PS and encouraging higher ZP were chosen for further experiments were intended to enhance anticancer action and apoptotic behavior. Formulations were showed biphasic release profile with extended release manner (Korsmeyer-Peppas model with a diffusion-controlled mechanism). The NPs effect on lung cancer cells with high specificity and affinity was demonstrated by MTT study. It was found that the effect of IBU was increased 4-28 times over the pure form. Annexin V-FITC/PI staining method, FITC Active Caspase-3 staining method and mitochondrial membrane potential detection analyses was performed to determine the apoptotic pathways by flow cytometry. Conclusion: E coded NP is selected as a promising candidate with its highly specific affinity for human lung adenocarcinoma cells and could induce cell death effectively and be a potent system to treat lung cancer.
1 November 2015 in International Journal of Pharmaceutics